title: Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601.
abstract: Duloxetine is an effective treatment for oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN). However, predictors of duloxetine response have not been adequately explored. The objective of this secondary and exploratory analysis was to identify predictors of duloxetine response in patients with painful oxaliplatin-induced CIPN. Patients (N = 106) with oxaliplatin-induced painful CIPN were randomised to receive duloxetine or placebo. Eligible patients had chronic CIPN pain and an average neuropathic pain score ≥4/10. Duloxetine/placebo dose was 30 mg/day for 7 days, then 60 mg/day for 4 weeks. The Brief Pain Inventory-Short Form and the EORTC QLQ-C30 were used to assess pain and quality of life, respectively. Univariate and multiple logistic regression analyses were performed to identify demographic, physiologic and psychological predictors of duloxetine response. Higher baseline emotional functioning predicted duloxetine response (≥30% reduction in pain; OR 4.036; 95% CI 0.999-16.308; p = 0.050). Based on the results from a multiple logistic regression using patient data from both the duloxetine and placebo treatment arms, duloxetine-treated patients with high emotional functioning are more likely to experience pain reduction (p = 0.026). In patients with painful, oxaliplatin-induced CIPN, emotional functioning may also predict duloxetine response. ClinicalTrials.gov, Identifier NCT00489411.
authors.affiliation: PhD program, University of Michigan School of Nursing, Ann Arbor, MI.
authors.forename: E M L
authors.initials: EM
authors.lastname: Smith
authors.affiliation: Alliance Statistics and Data Center, Duke University, Durham, NC.|Department of Biostatistics and Bioinformatics, Duke University, Durham, NC.|School of Public Health, Li Ka Shing Faculty of Medicine, Hong Kong SAR, China.
authors.forename: H
authors.initials: H
authors.lastname: Pang
authors.affiliation: Alliance Statistics and Data Center, Duke University, Durham, NC.
authors.forename: C
authors.initials: C
authors.lastname: Ye
authors.affiliation: Alliance Statistics and Data Center, Duke University, Durham, NC.|Department of Biostatistics and Bioinformatics, Duke University, Durham, NC.
authors.forename: C
authors.initials: C
authors.lastname: Cirrincione
authors.affiliation: Cancer Supportive Services program, Continuum Cancer Centers of New York: Beth Israel and St. Luke's-Roosevelt, New York, NY, USA.
authors.forename: S
authors.initials: S
authors.lastname: Fleishman
authors.affiliation: The Ohio State University Comprehensive Cancer Center, College of Medicine, Department of Internal Medicine, Columbus, OH, USA.
authors.forename: E D
authors.initials: ED
authors.lastname: Paskett
authors.affiliation: Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
authors.forename: T
authors.initials: T
authors.lastname: Ahles
authors.affiliation: University of Illinois College of Pharmacy (Emeritus Faculty), Chicago, IL, USA.
authors.forename: L R
authors.initials: LR
authors.lastname: Bressler
authors.affiliation: Illinois Oncology Research Association, Peoria, IL, USA.
authors.forename: N
authors.initials: N
authors.lastname: Le-Lindqwister
authors.affiliation: Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
authors.forename: C E
authors.initials: CE
authors.lastname: Fadul
authors.affiliation: Mayo Clinic, Rochester, Rochester, MN, USA.
authors.forename: C
authors.initials: C
authors.lastname: Loprinzi
authors.affiliation: Mount Sinai Medical Center, Division of Hematology/Medical Oncology: Tisch Cancer Institute, New York, NY, USA.
authors.forename: C L
authors.initials: CL
authors.lastname: Shapiro
mesh_terms: D000328:Adult; D000368:Aged; D000700:Analgesics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000068736:Duloxetine Hydrochloride / Q000627:therapeutic use*; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000009:adverse effects*; D000077150:Oxaliplatin; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000523:psychology; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D000700:Analgesics; D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000068736:Duloxetine Hydrochloride
keywords: Duloxetine; chemotherapy-induced peripheral neuropathy; oxaliplatin; pain